University of Miami
Coral Gables, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Primary biliary cholangitis
FollowWhat is new in Primary biliary cholangitis research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 2mg CS0159Phase 3 · NCT05896124 · NCT07282353
- Bezafibrate 200 mg in addition to UDCA therapyPhase 3 · NCT06443606
- Bezafibrate 400 mg in addition to UDCA therapyPhase 3 · NCT06443606
- ElafibranorPhase 3 · NCT06016842 · NCT06730061
- Elafibranor 80mgPhase 3 · NCT04526665
- FenofibratePhase 3 · NCT02823366 · NCT06174402 · NCT06365424 · NCT07296458 · NCT07104201 · NCT06755151
- Fenofibrate Combined With Ursodeoxycholic AcidPhase 3 · NCT05751967
- Fenofibrate in Combination With Ursodeoxycholic AcidPhase 3 · NCT06755541
- LinerixibatPhase 3 · NCT07860710 · NCT04167358
- Saroglitazar Magnesium 1 mgPhase 3 · NCT07424677 · NCT06427395 · NCT07216235 · NCT06825559
- SeladelparPhase 3 · NCT06051617 · NCT07841977
- Seladelpar 10 mg CapsulePhase 3 · NCT03301506
- Seladelpar 5 mg CapsulePhase 3 · NCT03301506
- UDCAPhase 3 · NCT02823366 · NCT06174402 · NCT06365424 · NCT05749822
- UDCA (Ursodeoxycholic acid)Phase 3 · NCT06591468 · NCT07296458
- Fenofibrate 200mgPhase 2/3 · NCT05749822
- PrednisonePhase 2/3 · NCT06591468
- Cilofexor Dose APhase 2 · NCT07841977
- Cilofexor Dose BPhase 2 · NCT07841977
- NalmefenePhase 2 · NCT06733519
- Nemolizumab-iltoPhase 2 · NCT07843420
- PTM Cilofexor Dose APhase 2 · NCT07841977
- PTM Cilofexor Dose BPhase 2 · NCT07841977
- PTM SeladelparPhase 2 · NCT07841977
- Upadacitinib 15 MGPhase 2 · NCT07678645
- VolixibatPhase 2 · NCT05050136
- hUC-MSC Dose Level 1Phase 1/2 · NCT07795151
- hUC-MSC Dose Level 2Phase 1/2 · NCT07795151
- Standard background therapyPhase 1/2 · NCT07795151
Closest to patients
- Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)Hospital Universitario Marqués de Valdecilla · Santander, Spain + 97 more hospitalsPhase 3Primary completion 2023
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CholangitisFenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CholangitisNanjing Drum Tower hospital · Nanjing, China + 11 more hospitalsPhase 2/3Results expected 2026
- Linerixibat Long-term Safety, and Tolerability StudyLinerixibat Long-term Safety, and Tolerability StudyPlymouth, United Kingdom + 85 more hospitalsPhase 3Results expected 2026
Choose one to continue
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial.
Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial.
Hepatology (Baltimore, Md.)
PubMed · PMID 42987205Publication
Primary Biliary Cholangitis Unmasked in Metabolic Dysfunction-Associated Steatohepatitis: When a Correct Diagnosis Is Incomplete.
Primary Biliary Cholangitis Unmasked in Metabolic Dysfunction-Associated Steatohepatitis: When a Correct Diagnosis Is Incomplete.
The Kaohsiung journal of medical sciences
PubMed · PMID 42972867Publication
TRENDS IN HOSPITALIZATIONS, COSTS, AND IN-HOSPITAL MORTALITY IN PRIMARY BILIARY CHOLANGITIS: A DECADE OF REAL-WORLD EVIDENCE FROM BRAZIL'S UNIFIED HEALTH SYSTEM.
TRENDS IN HOSPITALIZATIONS, COSTS, AND IN-HOSPITAL MORTALITY IN PRIMARY BILIARY CHOLANGITIS: A DECADE OF REAL-WORLD EVIDENCE FROM BRAZIL'S UNIFIED HEALTH SYSTEM.
Arquivos de gastroenterologia
PubMed · PMID 42987037Publication
Relationship of Biochemical Response as Surrogate Endpoints with Long-Term Outcomes in Primary Biliary Cholangitis: A Global Systematic Review and Meta-Analysis.
Relationship of Biochemical Response as Surrogate Endpoints with Long-Term Outcomes in Primary Biliary Cholangitis: A Global Systematic Review and Meta-Analysis.
Journal of health economics and outcomes research
PubMed · PMID 42968947
Organisations that can help
Helplines, patient groups and support services for you and your family.
International & European
European Liver Patients' Association (ELPA)
European umbrella of national liver patient groups: liver disease information, HCC patient guide (with ESMO), clinical trial finder and liver cancer advocacy; points patients to member groups.
Visit site: European Liver Patients' Association (ELPA)European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
Visit site: European Patients' Forum (EPF)EURORDIS – Rare Diseases Europe
Alliance of over 1,000 rare disease patient organisations, with a list of rare disease helplines by country.
Visit site: EURORDIS – Rare Diseases EuropeGlobal Liver Institute (GLI)
Global liver health advocacy body with a Liver Cancers Council, patient/caregiver education events and advocate training; not a direct support service.
Phone: +1 800 845 5910
Visit site: Global Liver Institute (GLI)International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Visit site: International Alliance of Patients' Organizations
Frontlight is not affiliated with these organisations; we list them because they help.
Checked automatically every 90 days.
Find fellow researchers
Groups with active Primary biliary cholangitis work.
Gilead Sciences (United States)
Foster City, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of California, Davis
Davis, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Newcastle University
Newcastle upon Tyne, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Liver Institute Northwest
Seattle, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Milano-Bicocca
Milan, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
Toronto General Hospital
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
University of California Davis Medical Center
Sacramento, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
The University of Texas Southwestern Medical Center
Dallas, United States
Team details appear once the team leader joins.
Is this your team? Claim it